Richard Macdonell

Exploration of factors which influence treatment decisions of patients with Multiple Sclerosis

B Bardsley, JM Haynes, E Cinc, E Heriot, K-J Lazarus, M McMurtrie, RAL Macdonell

Conference Proceedings  |  2020  |  MULTIPLE SCLEROSIS JOURNAL

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies

Giancarlo Comi, Raed Alroughani, Aaron L Boster, Ann D Bass, Regina Berkovich, Oscar Fernandez, Ho Jin Kim, Volker Limmroth, Jan Lycke, Richard AL Macdonell, Basil Sharrack, Barry A Singer, Patrick Vermersch, Heinz Wiendl, Tjalf Ziemssen, Alan Jacobs, Nadia Daizadeh, Claudio E Rodriguez, Anthony Traboulsee

Journal article  |  2019  |  Multiple Sclerosis Journal

Alemtuzumab improves disability and quality of life outcomes over 8 years in patients with RRMS

H Wiendl, RA Aburashed, R Alroughani, A Boster, A Chan, D Dive, S Eichau, D Kantor, HJ Kim, C LaGanke, J Lycke, RAL Macdonell, C Pozzilli, TF Scott, P Vermersch, Z Choudhry, N Daizadeh, DP Baker, S Hunter

Conference Proceedings  |  2019  |  MULTIPLE SCLEROSIS JOURNAL

Exploration of factors which influence treatment decisions of patients with multiple sclerosis

B Bardsley, JM Haynes, E Cinc, E Heriot, K-J Lazarus, M McMurtrie, RAL Macdonell

Conference Proceedings  |  2019  |  MULTIPLE SCLEROSIS JOURNAL

Real-world Efficacy of Delayed-Release Dimethyl Fumarate in Early Multiple Sclerosis: Interim Results from ESTEEM

Kathryn Giles, Konstantin Balashov, Cynthia C Jones, Richard Macdonell, Catherine Miller, Joerg Windsheimer, Fan Wu, Nicholas J Everage

Conference Proceedings  |  2019  |  NEUROLOGY

Treatment With Additional Courses of Alemtuzumab Improves Clinical and MRI Outcomes in RRMS Patients With Disease Activity After Three Courses: Analysis of CARE-MS Patients Who Received >= 4 Courses

Regina Berkovich, Ann D Bass, Aaron Boster, Giancarlo Comi, Oscar Fernandez, Ho Jin Kim, Volker Limmroth, Jan Lycke, Richard AL Macdonell, Sven Schippling, Barry A Singer, Patrick Vermersch, Heinz Wiendl, Tjalf Ziemssen, Luke Chung, Nadia Daizadeh, Claudio E Rodriguez, Anthony Traboulsee

Conference Proceedings  |  2019  |  NEUROLOGY

Brain Volume Loss and Cognition in Teriflunomide-Treated Patients in TEMSO

Jens Wuerfel, Richard Macdonell, Maria Sormani, Aaron Miller, Ludwig Kappos, Young-Min Lim, Deyanira Ramirez, Bassem Yamout, Kathleen Somera-Molina, Elizabeth Poole, Till Sprenger

Conference Proceedings  |  2019  |  NEUROLOGY

A Prospective Study of Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Identifying Ultrasonographic Features for Diagnosis and Prognosis

Nicholas Crump, Michael Cartwright, Richard Macdonell

Conference Proceedings  |  2019  |  NEUROLOGY

Long-Term Efficacy and Safety of Teriflunomide: An Analysis of Pooled Clinical Trials

Mark Freedman, Jihad Inshasi, Lluis Ramio-Torrenta, Mauro Zaffaroni, Jerome de Seze, Suk-won Ahn, Richard Macdonell, Aaron Miller, Boris Kallmann, David Rog, Myriam Benamor, Philippe Truffinet, Jeffrey Chavin, Elizabeth Poole, Christine Lebrun-Frenay

Conference Proceedings  |  2019  |  MULTIPLE SCLEROSIS JOURNAL

Additional Courses of Alemtuzumab Improved Clinical and MRI Outcomes in Pooled CARE-MS I and II Patients With Disease Activity After Two Courses: Analysis of Patients Who Received >= 3 Courses

HJ Kim, A Traboulsee, AD Bass, A Boster, R Berkovich, G Comi, O Fernandez, V Limmroth, J Lycke, RAL Macdonell, S Schippling, P Vermersch, H Wiendl, T Ziemssen, L Chung, N Daizadeh, CE Rodriguez, BA Singer

Conference Proceedings  |  2019  |  MULTIPLE SCLEROSIS JOURNAL